Instgra 50mg (Dolutegravir)

DESCRIPTION

Instgra tablets are containing a functioning substance known as Dolutegravir, which is an inhibitor of human immunodeficiency infection Integrase strand transmission. Instgra tablet is a physician endorsed drug, which is supported by FDA for the HIV-1 treatment.

Dolutegravir isn't utilized all things considered; it might consolidate with another against retroviral solutions. Instgra tablets are not ready to cure the disease; just it might decrease the spreading and drains

INDICATION

Instgra and are hostile to retro viral medications, utilized as a part of the treatment of HIV-1 disease, to anticipate facilitate ailment AIDS. Instgra and are typically utilized as a part of mix, for removing better hostile to retro viral action. Instgra utilized as a part of adults and pediatric with body weight of no less than 30kg.

MECHANISM OF ACTION

Instgra (Dolutegravir) contains antagonistic to viral property against HIV compose I infection. Instgra is classified as an Integrase inhibitor, which can prepared to limit HIV cell improvement by interfering with Integrase definitive to the dynamic site and blockade of strands trade step happened. The viral DNA mix into have cells get stopped This trade method is responsible for HIV cell increment cycle. This prompts impediment of viral activity

ADME PROPERTIES

ABSORPTION

Maximum plasma concentration time of Dolutegravir is 2 to 3 hours The steady state level reaches within 5 days

DISTRIBUTION

Dolutegravir is highly bound to human plasma protein at 98.9%

METABOLISM

The metabolism of Dolutegravir is occurs through UGT1A1 with some additional contribution from CYP3A.

ELIMINATION

The Dolutegravir half life of is 14 hours. The major route of elimination is urine & as an unchanged form through feces.

DOSAGE MANAGEMENT

INSTGRA DOSAGE

In Instgra measurement considers, Creatinine freedom, urine glucose, urine protein esteem ought to be explored. Instgra containing 50mg of Dolutegravir.

DOSAGE RECOMMENDATION

The standard measurement of Instgra is one tablet of 50mg to be taken as a solitary dosage as orally. Instgra can be taken with or without food but probably taken with food to enhance exposure. In adults: INSTI (Integrase strand transfer inhibitor)

FOR NEW PATIENTS OR EXPERIENCED INSTI NEW OR VIROLOGICALLY RESTRAINED

The recommended dose of Instgra 50mg should be taken as once a day

FOR NEW OR EXPERIENCED INSTI NEW BY COMBINING WITH UGT1A OR CYP3A INDUCERS

The recommended dosage of Instgra is 50mg should be given as two times a day

FOR INSTI ALREADY TREATED WITH CERTAIN INSTI RELATED RESISTANCE ALTERNATIVES

The recommended dosage of Instgra is 50mg should be given as two times a day

IN PEDIATRIC

The recommended dosage of Instgra for 30 to less than 40kg patients: 35mg should be taken as a once a day For 40kg or greater patients: The prescribed dosage is 50mg once daily.

SIDE EFFECTS
UNDESIRABLE EFFECTS OF INSTGRA
For Instgra ; The adverse effects occur in this therapy; Immune reconstitution syndrome Liver toxicity Anaphylactic reactions

THE MOST COMMON SIDE EFFECTS LIKE

Insomnia Anxiety Depression Creatine kinase elevation Increase in lipase Neutrophils elevation

PRECAUTION

SAFETY PRECAUTIONS OF INSTGRA

Hypersensitivity reaction: This may occur due to contraindication Lack of virological response during drug interaction: The Resistance of Instgra may occur in some patients during concomitant use with some drugs. Immune reconstitution syndrome: Some immune restructuring ailment is occurred during the initial stage of anti-retro viral therapy Liver damage: Elevation of AST & ALT levels causing liver damage; to avoid this problem monitor the patients with frequent liver function test.

DRUG INTERACTION

Instgra combines with drugs excreted through OCT2 or MATE1 (dofetilide or metformin), causes elevation of plasma concentration of these drugs. Instgra combined with etravirine causes decrease in plasma concentration of Dolutegravir.

Instgra concurrently used with anti-mycobacterials, anti-convulsants or herbal products causes depletion in plasma concentration of Dolutegravir. Dolutegravir is a substrate of UGT1A3, UGT1A9, BCRP & P-gp transporters. Instgra combined with the drug which prohibits these enzymes or transporters cause, increasing the plasma concentration of Dolutegravir.

Instgra tablets is concomitant use with non-nucleoside reverse transcriptase inhibitors; causing depletion of effect of concentration of Instgra . If Instgra tablets is combines with protease inhibitor causes decreasing in plasma concentration of Dolutegravir.

CONTRAINDICATION
In Instgra causes some hypersensitivity reaction to the patients who are contraindicated to the component of Instgra tablet.

PREGNANCY

The pregnancy category of Dolutegravir is B Utilizing Instgra in pregnancy condition with alert, simply in the wake of knowing the hazard components to the hatchling of these items Most of the patients placental change happens, in such conditions discontinue the use of these compounds.

LACTATION

In HIV conditions, generally Breast feeding is not recommended, it may have chance to transfer virus from mother to fetus. Avoid using the drug during feeding.

PEDIATRIC

The potency of the Instgra should not be evaluated in the pediatric patients with the body weight of less than 25kg.

RENAL IMPAIRMENT

Dosage adjustment is not recommended for both severe renal & hepatic impaired patients.

STORAGE

Instgra container should be stored at 25°C, keep the container away from light, moisture & heat.

MISSED DOSE

Instgra , are anti-retroviral medicines, if missed dose occurred during the course of therapy, must be consult with medical practitioner and follow the instruction as per their advice. Or , the missed dose should be avoided and follow the regular schedule.

OVER DOSAGE

There are no specific antitoxin is given for over dosage of Instgra , because Dolutegravir is highly bound to human plasma protein.